Krystal Biotech to Present at Upcoming Scientific Conferences
Krystal Biotech (NASDAQ: KRYS) has announced its participation in multiple scientific conferences during May and June 2025, showcasing developments across lung, eye, and skin programs.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Krystal Biotech (NASDAQ: KRYS) has announced its participation in multiple scientific conferences during May and June 2025, showcasing developments across lung, eye, and skin programs.
Key presentations include:
- An oral presentation on HSV-1 vector systems for respiratory tissues at the ASGCT 28th Annual Meeting on May 17
- A poster presentation on KB707 immunotherapy for lung tumors at ASCO Annual Meeting on June 2
- Research on KB801 gene therapy for corneal wounds at ARVO 2025 on May 5
- Findings on HSV-1-based gene therapy for Hailey-Hailey and Darier diseases at SID 2025 on May 9
All presentation materials will be made available on the company's investor relations website after the conferences.
Details
News Market Reaction – KRYS
The recorded move for KRYS in the trading session of this news was +2.00%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PITTSBURGH, April 24, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that the Company will be presenting on multiple programs in the lung, eye, and skin at upcoming scientific conferences being held in May and June.
Presentation details are outlined below.
American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting
Invited Oral Presentation
- Title: HSV-1 as a vector system for targeting respiratory tissues in genetic pulmonary disease
- Presenter: Trevor Parry, PhD
- Date and Time: May 17, 2025 at 8:50AM CT
2025 American Society of Clinical Oncology (ASCO) Annual Meeting
Poster Presentation
- Title: Inhaled KB707, a novel HSV-based immunotherapy, as a monotherapy in patients with advanced solid tumor malignancies affecting the lungs: Efficacy and safety results from a phase 1/2 study
- Presenter: Wen Wee Ma, MD, Enterprise Vice Chair, Research, Cancer Institute, Cleveland Clinic
- Date and Time: June 2, 2025 from 1:30PM to 4:30PM CT
- Poster Session or Category: Developmental Therapeutics – Immunotherapy
- Abstract Number: 2575
- Poster Bd Number: 222
Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting
Poster Presentation
- Title: Topical application of the HSV-1-based gene therapy vector KB801 results in sustained nerve growth factor expression in wounded murine corneas
- Presenter: Haley Cartwright, PhD
- Date and Time: May 5, 2025 from 3:00PM to 4:45PM MT
- Poster Session or Category: 258 – Preclinical Therapeutics
- Poster Number: B0154
Society for Investigative Dermatology (SID) 2025 Annual Meeting
Poster Presentation
- Title: Expansion of an HSV-1-based gene therapy platform to treat Hailey-Hailey and Darier diseases
- Presenter: Bruce Nmezi, PhD
- Date and Time: May 9, 2025 from 4:30PM to 6:00PM PT
- Poster Session or Category: Genetic Disease, Gene Regulation, Gene Therapy & Epigenetics
- Poster Number: 0554
Additional presentation details will be available to conference attendees. Following completion of each conference, presentation slides or posters, as applicable, will also be available to view online on the Investor section of the Company’s website.
About Krystal Biotech, Inc.
Krystal Biotech, Inc. (NASDAQ: KRYS) is a fully integrated, commercial-stage, global biotechnology company focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK® is the Company’s first commercial product, the first-ever redosable gene therapy, and the first medicine approved by the FDA for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines in respiratory, oncology, dermatology, ophthalmology, and aesthetics. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit http://www.krystalbio.com, and follow @KrystalBiotech on LinkedIn and X (formerly Twitter).
CONTACT
Investors and Media:
Stéphane Paquette, PhD
Krystal Biotech
spaquette@krystalbio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.